The Experts below are selected from a list of 1425561 Experts worldwide ranked by ideXlab platform
Martin H. Prins - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of venous thromboembolism with vitamin K antagonists: Patients' Health state valuations and treatment preferences: Patients' Health state valuations and treatment preferences
Journal of Thrombosis and Haemostasis, 2004Co-Authors: Mirjam Locadia, Patrick M.m. Bossuyt, Peep F. M. Stalmeier, Mirjam A. G. Sprangers, C.j.j. Van Dongen, Saskia Middeldorp, Ivan Bank, J.w.m. Van Der Meer, K. Hamulyák, Martin H. PrinsAbstract:Determining the optimal duration of vitamin K antagonist (VKA) therapy for Patients with venous thromboembolism (VTE) requires a weighting of the benefits and risks of treatment. The objectives of our study were to investigate patient variability in Health state valuations associated with VKA therapy and treatment preferences, and to investigate the extent to which valuations and treatment preferences are associated with prior experience with these Health states and other patient characteristics. Valuations of outcomes after VTE scaled from 0 (tantamount to death) to 1 (tantamount to perfect Health) were elicited from 53 Patients who had experienced VTE, 23 Patients who had experienced major bleeding during treatment, and 48 Patients with the post-thrombotic syndrome. In addition, Patients’ treatment preferences were evaluated using treatment trade-off questions. Median Health state valuations ranged from 0.33 for ‘non-fatal haemorrhagic stroke’ to 0.96 for ‘no VKA treatment’.Variability between Patients was substantial. Patients’ treatment preferences also varied: 25% of Patients chose cessation of treatment, regardless of the probability of recurrent VTE presented, whereas 23% of Patients were never willing to choose cessation of treatment. Differences in valuations and treatment preferences were not associated with type of event experienced. Due to the substantial and unpredictable variability in valuations and treatment preferences, recommendations regarding treatment duration should be tailored to Patients’ specific values and concerns.
-
treatment of venous thromboembolism with vitamin k antagonists Patients Health state valuations and treatment preferences
Thrombosis and Haemostasis, 2004Co-Authors: Mirjam Locadia, Patrick M.m. Bossuyt, Peep F. M. Stalmeier, Mirjam A. G. Sprangers, Saskia Middeldorp, Ivan Bank, K. Hamulyák, Carlo J Van Dongen, Jan Van Der Meer, Martin H. PrinsAbstract:Determining the optimal duration of vitamin K antagonist (VKA) therapy for Patients with venous thromboembolism (VTE) requires a weighting of the benefits and risks of treatment. The objectives of our study were to investigate patient variability in Health state valuations associated with VKA therapy and treatment preferences, and to investigate the extent to which valuations and treatment preferences are associated with prior experience with these Health states and other patient characteristics. Valuations of outcomes after VTE scaled from 0 (tantamount to death) to 1 (tantamount to perfect Health) were elicited from 53 Patients who had experienced VTE, 23 Patients who had experienced major bleeding during treatment, and 48 Patients with the post-thrombotic syndrome. In addition, Patients’ treatment preferences were evaluated using treatment trade-off questions. Median Health state valuations ranged from 0.33 for ‘non-fatal haemorrhagic stroke’ to 0.96 for ‘no VKA treatment’.Variability between Patients was substantial. Patients’ treatment preferences also varied: 25% of Patients chose cessation of treatment, regardless of the probability of recurrent VTE presented, whereas 23% of Patients were never willing to choose cessation of treatment. Differences in valuations and treatment preferences were not associated with type of event experienced. Due to the substantial and unpredictable variability in valuations and treatment preferences, recommendations regarding treatment duration should be tailored to Patients’ specific values and concerns.
Marie-christine Jaffar-bandjee - One of the best experts on this subject based on the ideXlab platform.
-
Rift Valley Fever Outbreak, Mayotte, France, 2018–2019
Emerging Infectious Diseases, 2020Co-Authors: Hassani Youssouf, Louis Collet, Marion Subiros, Genevieve Dennetiere, Laure Dommergues, Amandine Pauvert, Patrick Rabarison, Christelle Vauloup-fellous, Gilles Le Godais, Marie-christine Jaffar-bandjeeAbstract:From November 2018 through July 2019, an outbreak of Rift Valley fever in humans occurred in Mayotte, France; 142 cases were confirmed. Exposure to animals or their biological fluid was reported by 73% of Patients. Health authorities have been implementing control measures, including veterinary surveys, vector control interventions, and prevention measures.
Patrick M.m. Bossuyt - One of the best experts on this subject based on the ideXlab platform.
-
The influence of medical testing on Patients’ Health: an overview from the gynecologists’ perspective
BMC Medical Informatics and Decision Making, 2013Co-Authors: Myra Cb Van Zwieten, Patrick M.m. Bossuyt, Karel Gm Moons, Marcel Gw Dijkgraaf, Kirsten J Mccaffery, Brent C OpmeerAbstract:Background A medical tests may influence the Health of Patients by guiding clinical decisions, such as treatment in case of a positive test result. However, a medical test can influence the Health of Patients through other mechanisms as well, like giving reassurance. To make a clinical recommendation about a medical test, we should be aware of the full range of effects of that test on Patients. This requires an understanding of the range of effects that medical testing can have on Patients. This study evaluates the mechanisms through which medical testing can influence Patients’ Health, other than the effect on clinical management, from a gynecologist’s perspective. Methods A qualitative study in which explorative focus groups were conducted with gynecologists, gynecological residents and gynecological M.D. researchers (n = 43). Discussions were transcribed verbatim. Transcriptions were coded inductively and analyzed by three researchers. Results All participants contributed various clinical examples in which medical testing had influenced Patients’ Health. Clinical examples illustrated that testing, in itself or in interaction with contextual factors, may provoke a wide range of effects on Patients. Our data showed that testing can influence the doctor’s perceptions of the Patients’ appraisal of their illness, their perceived control, or the doctor-patient relationship. This may lead to changes in psychological, behavioral, and/or medical outcomes, both favorably or unfavorably. The data were used to construct a conceptual framework of effects of medical testing on Patients. Conclusions Besides supporting clinical decision making, medical testing may have favorable or unfavorable effects on Patients’ Health though several mechanisms.
-
Treatment of venous thromboembolism with vitamin K antagonists: Patients' Health state valuations and treatment preferences: Patients' Health state valuations and treatment preferences
Journal of Thrombosis and Haemostasis, 2004Co-Authors: Mirjam Locadia, Patrick M.m. Bossuyt, Peep F. M. Stalmeier, Mirjam A. G. Sprangers, C.j.j. Van Dongen, Saskia Middeldorp, Ivan Bank, J.w.m. Van Der Meer, K. Hamulyák, Martin H. PrinsAbstract:Determining the optimal duration of vitamin K antagonist (VKA) therapy for Patients with venous thromboembolism (VTE) requires a weighting of the benefits and risks of treatment. The objectives of our study were to investigate patient variability in Health state valuations associated with VKA therapy and treatment preferences, and to investigate the extent to which valuations and treatment preferences are associated with prior experience with these Health states and other patient characteristics. Valuations of outcomes after VTE scaled from 0 (tantamount to death) to 1 (tantamount to perfect Health) were elicited from 53 Patients who had experienced VTE, 23 Patients who had experienced major bleeding during treatment, and 48 Patients with the post-thrombotic syndrome. In addition, Patients’ treatment preferences were evaluated using treatment trade-off questions. Median Health state valuations ranged from 0.33 for ‘non-fatal haemorrhagic stroke’ to 0.96 for ‘no VKA treatment’.Variability between Patients was substantial. Patients’ treatment preferences also varied: 25% of Patients chose cessation of treatment, regardless of the probability of recurrent VTE presented, whereas 23% of Patients were never willing to choose cessation of treatment. Differences in valuations and treatment preferences were not associated with type of event experienced. Due to the substantial and unpredictable variability in valuations and treatment preferences, recommendations regarding treatment duration should be tailored to Patients’ specific values and concerns.
-
treatment of venous thromboembolism with vitamin k antagonists Patients Health state valuations and treatment preferences
Thrombosis and Haemostasis, 2004Co-Authors: Mirjam Locadia, Patrick M.m. Bossuyt, Peep F. M. Stalmeier, Mirjam A. G. Sprangers, Saskia Middeldorp, Ivan Bank, K. Hamulyák, Carlo J Van Dongen, Jan Van Der Meer, Martin H. PrinsAbstract:Determining the optimal duration of vitamin K antagonist (VKA) therapy for Patients with venous thromboembolism (VTE) requires a weighting of the benefits and risks of treatment. The objectives of our study were to investigate patient variability in Health state valuations associated with VKA therapy and treatment preferences, and to investigate the extent to which valuations and treatment preferences are associated with prior experience with these Health states and other patient characteristics. Valuations of outcomes after VTE scaled from 0 (tantamount to death) to 1 (tantamount to perfect Health) were elicited from 53 Patients who had experienced VTE, 23 Patients who had experienced major bleeding during treatment, and 48 Patients with the post-thrombotic syndrome. In addition, Patients’ treatment preferences were evaluated using treatment trade-off questions. Median Health state valuations ranged from 0.33 for ‘non-fatal haemorrhagic stroke’ to 0.96 for ‘no VKA treatment’.Variability between Patients was substantial. Patients’ treatment preferences also varied: 25% of Patients chose cessation of treatment, regardless of the probability of recurrent VTE presented, whereas 23% of Patients were never willing to choose cessation of treatment. Differences in valuations and treatment preferences were not associated with type of event experienced. Due to the substantial and unpredictable variability in valuations and treatment preferences, recommendations regarding treatment duration should be tailored to Patients’ specific values and concerns.
-
systemic methotrexate therapy versus laparoscopic salpingostomy in Patients with tubal pregnancy part i impact on Patients Health related quality of life
Fertility and Sterility, 1998Co-Authors: Pythia T. Nieuwkerk, P J Hajenius, Wouter Wijker, Willem M Ankum, Fulco Van Der Veen, Patrick M.m. BossuytAbstract:Abstract Objective: To compare Patients' Health-related quality of life after systemic methotrexate therapy versus laparoscopic salpingostomy for tubal pregnancy. Design: Multicenter randomized clinical trial. Setting: Departments of obstetrics and gynecology of six Dutch hospitals. Patient(s): Hemodynamically stable Patients with a laparoscopically confirmed unruptured tubal pregnancy without signs of active bleeding, who were randomly assigned to undergo either systemic methotrexate therapy or laparoscopic salpingostomy. Intervention(s): Standard Health-related quality of life questionnaires administered before and 2 days, 2 weeks, 4 weeks, and 16 weeks after confirmative laparoscopy. Main Outcome Measure(s): Health-related quality of life. Result(s): Health-related quality of life was impaired most severely 2 days after confirmative laparoscopy in both treatment groups and improved during follow-up. Health-related quality of life was impaired more severely after systemic methotrexate therapy than after laparoscopic salpingostomy. Medically treated Patients had more limitations in physical functioning, role functioning, and social functioning; had worse Health perceptions, less energy, more pain, more physical symptoms, and a worse overall quality of life; and were more depressed than surgically treated Patients. Conclusion(s): Systemic methotrexate therapy had a more negative impact on Patients' Health-related quality of life than did laparoscopic salpingostomy. This negative impact on Patients' Health-related quality of life of systemic methotrexate therapy should be taken into account when deciding on the appropriate therapy for tubal pregnancy.
Mirjam Locadia - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of venous thromboembolism with vitamin K antagonists: Patients' Health state valuations and treatment preferences: Patients' Health state valuations and treatment preferences
Journal of Thrombosis and Haemostasis, 2004Co-Authors: Mirjam Locadia, Patrick M.m. Bossuyt, Peep F. M. Stalmeier, Mirjam A. G. Sprangers, C.j.j. Van Dongen, Saskia Middeldorp, Ivan Bank, J.w.m. Van Der Meer, K. Hamulyák, Martin H. PrinsAbstract:Determining the optimal duration of vitamin K antagonist (VKA) therapy for Patients with venous thromboembolism (VTE) requires a weighting of the benefits and risks of treatment. The objectives of our study were to investigate patient variability in Health state valuations associated with VKA therapy and treatment preferences, and to investigate the extent to which valuations and treatment preferences are associated with prior experience with these Health states and other patient characteristics. Valuations of outcomes after VTE scaled from 0 (tantamount to death) to 1 (tantamount to perfect Health) were elicited from 53 Patients who had experienced VTE, 23 Patients who had experienced major bleeding during treatment, and 48 Patients with the post-thrombotic syndrome. In addition, Patients’ treatment preferences were evaluated using treatment trade-off questions. Median Health state valuations ranged from 0.33 for ‘non-fatal haemorrhagic stroke’ to 0.96 for ‘no VKA treatment’.Variability between Patients was substantial. Patients’ treatment preferences also varied: 25% of Patients chose cessation of treatment, regardless of the probability of recurrent VTE presented, whereas 23% of Patients were never willing to choose cessation of treatment. Differences in valuations and treatment preferences were not associated with type of event experienced. Due to the substantial and unpredictable variability in valuations and treatment preferences, recommendations regarding treatment duration should be tailored to Patients’ specific values and concerns.
-
treatment of venous thromboembolism with vitamin k antagonists Patients Health state valuations and treatment preferences
Thrombosis and Haemostasis, 2004Co-Authors: Mirjam Locadia, Patrick M.m. Bossuyt, Peep F. M. Stalmeier, Mirjam A. G. Sprangers, Saskia Middeldorp, Ivan Bank, K. Hamulyák, Carlo J Van Dongen, Jan Van Der Meer, Martin H. PrinsAbstract:Determining the optimal duration of vitamin K antagonist (VKA) therapy for Patients with venous thromboembolism (VTE) requires a weighting of the benefits and risks of treatment. The objectives of our study were to investigate patient variability in Health state valuations associated with VKA therapy and treatment preferences, and to investigate the extent to which valuations and treatment preferences are associated with prior experience with these Health states and other patient characteristics. Valuations of outcomes after VTE scaled from 0 (tantamount to death) to 1 (tantamount to perfect Health) were elicited from 53 Patients who had experienced VTE, 23 Patients who had experienced major bleeding during treatment, and 48 Patients with the post-thrombotic syndrome. In addition, Patients’ treatment preferences were evaluated using treatment trade-off questions. Median Health state valuations ranged from 0.33 for ‘non-fatal haemorrhagic stroke’ to 0.96 for ‘no VKA treatment’.Variability between Patients was substantial. Patients’ treatment preferences also varied: 25% of Patients chose cessation of treatment, regardless of the probability of recurrent VTE presented, whereas 23% of Patients were never willing to choose cessation of treatment. Differences in valuations and treatment preferences were not associated with type of event experienced. Due to the substantial and unpredictable variability in valuations and treatment preferences, recommendations regarding treatment duration should be tailored to Patients’ specific values and concerns.
Hassani Youssouf - One of the best experts on this subject based on the ideXlab platform.
-
Rift Valley Fever Outbreak, Mayotte, France, 2018–2019
Emerging Infectious Diseases, 2020Co-Authors: Hassani Youssouf, Louis Collet, Marion Subiros, Genevieve Dennetiere, Laure Dommergues, Amandine Pauvert, Patrick Rabarison, Christelle Vauloup-fellous, Gilles Le Godais, Marie-christine Jaffar-bandjeeAbstract:From November 2018 through July 2019, an outbreak of Rift Valley fever in humans occurred in Mayotte, France; 142 cases were confirmed. Exposure to animals or their biological fluid was reported by 73% of Patients. Health authorities have been implementing control measures, including veterinary surveys, vector control interventions, and prevention measures.
